We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
THIS STUDY WILL RECRUIT PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS FOR ALL FORMS OF CANCER
Immune Checkpoint Inhibitor Genetics
Summary Title: Toxicites caused by immune checkpoint inhibitors used to treat cancers: are there differences in the genetic make-up of those patients who suffer side effects and those who do not?
All anti-cancer therapies cause toxicity and some individuals appear especially susceptible to the side-effects of particular treatments. This might be because of genes that we inherit. We can find out whether those genes exist by studying the clinical features and blood samples of a large set of cancer patients who have been treated with immune system boosters and looking for differences between those who develop severe toxicity, those who have mild toxicity and those who have no toxicity. We can also look at people with different types of toxicity, for example affecting different parts of the body. We will also study the clinical features and bloods samples of a group of participants who have autoimmune diseases but have not been treated with immune system boosters to assess whether there are any similarities in their inherited genes. If we find genes that affect the chances of toxic side-effects, we may be able to find out who is at greatest risk before they take the drugs and develop ways of preventing or minimising the side-effects.
Clinical details will be collected from the participant and clinical team in the form of a questionnaire, blood sampling will occur on a single occasion, either within routine clinical management or at the participants convenience.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Genetic epidemiology;
You can take part if:
You may not be able to take part if:
Unable or unwilling to provide informed consent and a sample of blood (or saliva) Aged less than 16 years old
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Birmingham and funded by CANCER RESEARCH UK; University of Birmingham; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 39433
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
